Microarray Analysis Market (2026-2036)

The growth of this market is driven principally by applications in which arrays retain a decisive cost and throughput advantage over sequencing, most notably population-scale genotyping for biobanks and national cohort programmes, array-based genotyping in livestock and crop breeding, pharmacogenomic genotyping, and chromosomal microarray analysis in prenatal and paediatric cytogenetics, where the test remains the covered standard in several payer policies. In addition, the continued development of array content for diverse ancestries and polygenic risk applications, the use of arrays as an affordable first-tier test ahead of selective sequencing, and the installed base of array instrumentation in clinical cytogenetics and agricultural genotyping laboratories support demand. Growth is nonetheless modest, because next-generation sequencing has displaced arrays in gene expression profiling and in much of discovery research, and this report forecasts a mature market growing slowly rather than an expanding one.

The Microarray Analysis Market, also referred to as the biochip market, array-based analysis market, or microarray technology market, comprises the consumables, instruments, software, and services used to perform parallel analysis of many biological targets immobilised in an ordered pattern on a solid support. The market includes DNA microarrays for genotyping, copy number analysis, methylation analysis, and gene expression profiling; protein and antibody microarrays for proteomic profiling, biomarker screening, and autoantibody detection; tissue and cell microarrays for pathology and histological screening; and other array formats including carbohydrate and small-molecule arrays. The market covers array consumables, which account for most recurring spending, scanners, hybridisation ovens, washing stations and automated array handling systems, analysis and interpretation software, and array-based genotyping and profiling services. The market ecosystem extends from array and instrument manufacturers and service providers to biobanks and national cohort programmes, clinical cytogenetics and molecular pathology laboratories, agricultural breeding organizations, pharmaceutical companies, and academic researchers.

Any credible assessment of this market must begin with the fact that next-generation sequencing has displaced microarrays from most of the applications in which arrays were once standard. Gene expression profiling has largely moved to RNA sequencing, which measures transcripts without the need for predefined probes and detects novel transcripts and splice variants that an array cannot. Discovery research has followed. The market that remains is therefore not a general-purpose research technology but a set of specific applications in which the economics or the regulatory position still favour arrays, and understanding which applications those are is the central analytical question for this market.

Population-scale genotyping is the largest of these applications and the most robust. Genotyping a known set of common variants on an array costs a fraction of sequencing a genome, and when combined with imputation against a reference panel it yields tens of millions of variant calls from a few hundred thousand directly measured positions. In the U.K., Our Future Health has genotyped 755,000 of its more than 2.02 million recruited participants using a genotyping array covering 686,416 variants, from which 159,587,100 imputed variants were generated, with the first array release in December 2023, the first imputed genotype release in December 2025, and the first genetic ancestry release in May 2026. That ratio, roughly 160 million imputed variants from fewer than 700,000 measured, is the economic argument for arrays in population cohorts, and it is why biobanks continue to genotype at scale rather than sequence.

Array content continues to be developed for this purpose. Thermo Fisher Scientific has extended its Axiom array portfolio for population-scale studies and pharmacogenomic research, including biobank-oriented arrays and the PangenomiX array designed to support population-scale disease studies and pharmacogenomics across diverse ancestries, reflecting continued investment in array content for large cohort genotyping. Investment in arrays designed for diverse ancestries and for pharmacogenomic content indicates that suppliers regard population genotyping as a durable rather than a declining application, and the growth of polygenic risk research, which depends on common variant genotyping across very large cohorts, reinforces that position.

Agricultural genotyping is the second substantial application and is commercially significant out of proportion to its visibility. In March 2026, Neogen Corporation announced the sale of its global genomics business, operating under the GeneSeek brand and including the Igenity and GGP array-based livestock genotyping portfolios, to Zoetis Inc. for USD 160 million, with the business having generated approximately USD 90 million in sales in fiscal 2025. Livestock genomic selection requires genotyping very large numbers of animals at low cost per sample, with no requirement to discover novel variation, which is precisely the case arrays serve best. The acquisition of an array-based livestock genotyping business generating approximately USD 90 million in annual sales by a major animal health company demonstrates that this application is regarded as strategically valuable rather than legacy.

Clinical cytogenetics sustains a protected position for arrays through payer policy. A payer medical policy revised in March 2026 provides coverage for chromosomal microarray analysis in invasive prenatal diagnosis, in fetuses with major structural abnormalities on ultrasound, in intrauterine fetal demise or stillbirth at 20 weeks or more, and after two or more miscarriages at 20 weeks or less, stating that the test can typically replace fetal karyotype, while declining to cover routine whole-genome or whole-exome sequencing for prenatal diagnosis outside clinical trials until sufficient peer-reviewed data and validation studies are published. Chromosomal microarray analysis detects copy number variation across the genome at a resolution far exceeding karyotype, is supported by extensive validation and professional guidance, and in several coverage policies is the reimbursed prenatal test while sequencing is not. This gives arrays a defended clinical application that is insulated from technology substitution for as long as the coverage position holds.

The commercial picture at the suppliers reflects this mixed position. In the second quarter of 2026, Illumina, Inc. reported microarrays and other revenue of USD 105 million, up 21% as reported but down 4% on a rest-of-world organic basis, against sequencing consumables revenue of USD 775 million in the same quarter, illustrating both the scale of array activity relative to sequencing and the uneven trajectory of array demand. Array revenue at the largest supplier is roughly one-seventh of sequencing consumable revenue and is not growing organically, which is consistent with a technology serving specific durable applications rather than expanding into new ones. Protein and tissue arrays occupy smaller niches, with protein arrays used in autoantibody and biomarker screening and tissue microarrays in pathology research, both facing competition from multiplexed immunoassay and spatial profiling methods.

The market includes Illumina and Thermo Fisher Scientific, which supply most genotyping and expression array capacity, Agilent Technologies, which supplies cytogenetics and expression arrays, Revvity and Bio-Rad Laboratories in selected formats, protein array providers including RayBiotech and Sengenics, tissue microarray and pathology suppliers including TissueArray and BioChain, and array-based genotyping service providers including Eurofins Scientific and, in agricultural genotyping, the GeneSeek business acquired by Zoetis. Participants compete on cost per sample, array content and ancestry coverage, call rate and data quality, throughput and automation, regulatory status for clinical use, and the quality of analysis software and imputation support.

At the same time, the market faces substantial and structural challenges, including continuing displacement by sequencing as sequencing costs fall, the inability of arrays to detect variants not represented on the array, which limits their use where novel variation matters, the gradual encroachment of low-pass whole-genome sequencing into population genotyping as an imputation alternative, the long-term risk that clinical coverage policies shift toward sequencing, and consolidation of the supplier base. As a result, participants that concentrate on applications where cost per sample is decisive, maintain content relevant to diverse populations and to pharmacogenomic and polygenic applications, and hold defended clinical positions are expected to retain the largest share of a market that is growing only slowly.